Prothena PRX012 shows amyloid reduction but higher ARIA-E rates; seeks partnership

PROTHENA CORP PUBLIC LTD CO

Phase 1 ASCENT: PRX012 400 mg achieved mean amyloid PET reduction to 27.47 CL at month 12.
ARIA-E rates at 400 mg (41.7%) and 200 mg (38.1%) exceeded those of FDA-approved anti-Aβ antibodies.
One death in 45 mg cohort deemed unrelated to study drug; injection site reactions low (4.1%).
Company plans to explore partnership to advance PRX012 and preclinical PRX012-TfR antibody.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.